Want to see HTFL full AI Analyst Report?
HTFL Stock Chart & Stats
$48.91
$0.48(1.99%)
At close: 4:00 PM EDT
$48.91
$0.48(1.99%)
Day’s Range― - ―
52-Week Range$20.13 - $54.32
Previous CloseN/A
Volume122.43K
Average Volume (3M)1.82M
Market Cap
$4.54B
Enterprise Value$2.40B
Total Cash (Recent Filing)$162.55M
Total Debt (Recent Filing)$27.13M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 18, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding86,953,630
10 Day Avg. Volume1,475,963
30 Day Avg. Volume1,822,046
Financial Highlights & Ratios
PEG Ratio2.03
Price to Book (P/B)8.27
Price to Sales (P/S)14.12
P/FCF Ratio-42.10
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue11.31
Enterprise Value/Gross Profit14.13
Enterprise Value/Ebitda-22.17
Forecast
1Y Price Target
$44.78Price Target Upside-8.45% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$248.94M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthStrong growth across Q2 and the full-year outlook indicates expanding clinical utilization and account penetration. Rising case volumes and increased U.S. revenue provide a durable foundation for scaling the software-based model over the next several quarters.
Expanding Gross MarginsSignificant margin expansion suggests that AI efficiencies, higher volume, and product mix are improving the economics of each analysis. If sustained, these gains can support operating leverage and move the company closer to its stated cash-flow profitability objective.
Clinical Differentiation And AdoptionA substantial clinical evidence base and differentiated lesion-specific testing can strengthen physician confidence and reinforce HeartFlow’s position in cardiac assessment. Durable utilization, alongside supportive professional guidance, may create adoption advantages as installed accounts expand.
Bears Say
Persistent Losses And Cash BurnThe company is growing and improving efficiency but still does not fund operations through internally generated cash. Continued negative cash flow and operating losses can require financing before profitability, limiting flexibility for investment and increasing execution pressure.
Plaque Adoption Remains EarlyThe Plaque opportunity is strategically important, yet current utilization remains early relative to its potential addressable use. Slow account ramping could delay revenue conversion and makes near-term growth increasingly dependent on sustained physician adoption and reimbursement progress.
Legal And Regulatory OverhangLong-running intellectual-property and government matters can consume management attention and financial resources while creating uncertainty around future operations. Even without an adverse outcome, prolonged proceedings may complicate planning and add an enduring execution risk.
HeartFlow, Inc. News
HTFL FAQ
What was HeartFlow, Inc.’s price range in the past 12 months?
HeartFlow, Inc. lowest stock price was $20.13 and its highest was $54.32 in the past 12 months.
What is HeartFlow, Inc.’s market cap?
HeartFlow, Inc.’s market cap is $4.54B.
When is HeartFlow, Inc.’s upcoming earnings report date?
HeartFlow, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 42 days.
How were HeartFlow, Inc.’s earnings last quarter?
HeartFlow, Inc. released its earnings results on Aug 13, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.064.
Is HeartFlow, Inc. overvalued?
According to Wall Street analysts HeartFlow, Inc.’s price is currently Overvalued.
Does HeartFlow, Inc. pay dividends?
HeartFlow, Inc. does not currently pay dividends.
What is HeartFlow, Inc.’s EPS estimate?
HeartFlow, Inc.’s EPS estimate is -0.1.
How many shares outstanding does HeartFlow, Inc. have?
HeartFlow, Inc. has 86,953,630 shares outstanding.
What happened to HeartFlow, Inc.’s price movement after its last earnings report?
HeartFlow, Inc. reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went up 35.698%.
Which hedge fund is a major shareholder of HeartFlow, Inc.?
Currently, no hedge funds are holding shares in HTFL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartFlow, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.78 (-8.45% Downside)
$44.78 (-8.45% Downside)
Blogger Sentiment
Bullish
HTFL Sentiment 88%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 68.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.5%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
116.15%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HeartFlow, Inc.
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
HTFL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong top-line momentum (48% YoY Q2 revenue growth), significant gross-margin expansion (770 bps YoY) and raised full-year guidance, supported by accelerating Plaque adoption, durable FFRCT utilization, a rich clinical evidence base, and a clear R&D pipeline. Offsets include remaining GAAP losses, early-stage Plaque penetration relative to its long-term potential, ongoing litigation, and pricing/ASP dynamics that could moderate in 2027. On balance, operational and financial progress, upgraded guidance, and a solid cash position outweigh the near-term risks.View all HTFL earnings summariesHTFL Stock 12 Month Forecast
Average Price Target
$44.78
▼(-8.45% Downside)
Technical Analysis
Ownership Overview
23.27% Insiders
27.21% Mutual Funds
1.17% Other Institutional Investors
36.51% Public Companies and
Individual Investors